Holen Sie sich die Stockscreener-App
4.10
2.24%
0.09
Schlusskurs vom Vortag:
$4.01
Offen:
$4.01
24-Stunden-Volumen:
843.32K
Relative Volume:
1.77
Marktkapitalisierung:
$286.23M
Einnahmen:
$63.39M
Nettoeinkommen (Verlust:
$-219.51M
KGV:
-1.2962
EPS:
-3.1631
Netto-Cashflow:
$-231.83M
1W Leistung:
+2.50%
1M Leistung:
-10.28%
6M Leistung:
-39.88%
1J Leistung:
-43.68%
1-Tages-Spanne:
$3.985
$4.19
1-Wochen-Bereich:
$3.92
$4.19
52-Wochen-Spanne:
$3.92
$9.1592
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Firmenname
Bicycle Therapeutics Plc Adr
Sektor
Branche
Telefon
011441223261503
Adresse
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
4.10 | 286.23M | 63.39M | -219.51M | -231.83M | -3.1631 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Hold |
| 2025-10-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | Eingeleitet | Stephens | Equal-Weight |
| 2024-09-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-07 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | Eingeleitet | Cowen | Outperform |
| 2022-07-28 | Eingeleitet | Barclays | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-04-13 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-02-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-12-09 | Eingeleitet | Needham | Buy |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Buy |
| 2021-04-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-04-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-14 | Eingeleitet | ROTH Capital | Buy |
| 2019-09-11 | Hochstufung | Goldman | Neutral → Buy |
| 2019-06-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-17 | Eingeleitet | Goldman | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
| 2019-06-17 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Bicycle Therapeutics Plc Adr Aktie (BCYC) Neueste Nachrichten
Price to earnings forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Enterprise value to EBIT forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:BCYC) - TradingView
Price to sales forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
50BA Forecast — Price Target — Prediction for 2027 - TradingView
Bicycle Therapeutics shareholders approve all proposals at annual general meeting - Investing.com South Africa
Bicycle Therapeutics’ SWOT analysis: stock navigates trial delays - Investing.com
After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC) - MSN
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Sees Significant Increase in Short Interest - MarketBeat
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - ChartMill
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicycle Therapeutics (BCYC) loses 19.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bicycle Therapeutics (BCYC) schedules 2026 AGM with director, pay and auditor votes - Stock Titan
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
Bicycle Therapeutics doses first patient in pancreatic cancer trial By Investing.com - Investing.com South Africa
Bicycle Therapeutics doses first patient in pancreatic cancer trial - Investing.com
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares of Stock - MarketBeat
Bicycle Therapeutics plc (BCYC) stock price, news, quote and history - Yahoo Finance UK
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bicycle Therapeutics (BCYC) proxy: June 17 AGM, board and pay votes (BCYC) - Stock Titan
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC) - Yahoo Finance
Bicycle Therapeutics (BCYC) Drops 19.0% Over the Past 4 Weeks, Reasons a Potential Turnaround Could Be Near - Bitget
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) Given New $15.00 Price Target at Needham & Company LLC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Given New $36.00 Price Target at Oppenheimer - Defense World
Bicycle Therapeutics stock price target lowered to $7 by RBC Capital - Investing.com South Africa
Citizens cuts Bicycle Therapeutics stock price target on strategic shift By Investing.com - Investing.com South Africa
Bicycle Therapeutics (BCYC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Truist cuts Bicycle Therapeutics stock price target on pipeline shift By Investing.com - Investing.com South Africa
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift By Investing.com - Investing.com India
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift - Investing.com
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Merit Medical Systems, Inc. (NASDAQ:MMSI) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Principal Financial Group Inc. Grows Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Finanzdaten der Bicycle Therapeutics Plc Adr-Aktie (BCYC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):